MLchartDataset catalogue

Daratumumab and hyaluronidase

Term · Oncology and biomedicine · MLC-T-ONC-002282

A combination of two drugs used alone or with other drugs to treat adults with certain types of multiple myeloma or light chain amyloidosis. It is also being studied in the treatment of other types of cancer. Daratumumab binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Hyaluronidase allows daratumumab to be given by injection under the skin. Daratumumab and hyaluronidase can be given in less time than daratumumab alone, which is given as an infusion. Also called Darzalex Faspro.

Table 1. Record
IdentifierMLC-T-ONC-002282
FieldOncology and biomedicine
SynonymsDarzalex Faspro
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-002282",
  "term": "Daratumumab and hyaluronidase",
  "field": "Oncology and biomedicine",
  "definition": "A combination of two drugs used alone or with other drugs to treat adults with certain types of multiple myeloma or light chain amyloidosis. It is also being studied in the treatment of other types of cancer. Daratumumab binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Hyaluronidase allows daratumumab to be given by injection under the skin. Daratumumab and hyaluronidase can be given in less time than daratumumab alone, which is given as an infusion. Also called Darzalex Faspro.",
  "synonyms": [
    "Darzalex Faspro"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/daratumumab-and-hyaluronidase/"
}

Record 5,692 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.